# A Clinical Trial to Evaluate the Efficacy and Safety of TQB3909 Tablets Versus Investigator's Choice in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

> **NCT07753369** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 128 (estimated)

## Conditions studied

- Small Lymphocytic Lymppho
- Relapsed/Refractory Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** TQB3909 Tablets
- **DRUG:** Bendamustine Injection
- **DRUG:** Rituximab injection
- **DRUG:** Lenalidomide Capsules

## Key facts

- **NCT ID:** NCT07753369
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08
- **Primary completion:** 2030-12
- **Final completion:** 2030-12
- **Target enrollment:** 128 (ESTIMATED)
- **Last updated:** 2026-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07753369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07753369, "A Clinical Trial to Evaluate the Efficacy and Safety of TQB3909 Tablets Versus Investigator's Choice in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07753369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*